Legislation of direct-to-consumer genetic testing in Europe: a fragmented regulatory landscape L Kalokairinou, HC Howard, S Slokenberga, E Fisher, M Flatscher-Thöni, ... Journal of Community Genetics 9, 117-132, 2018 | 112 | 2018 |
Third party interpretation of raw genetic data: an ethical exploration L Badalato, L Kalokairinou, P Borry European Journal of Human Genetics 25 (11), 1189-1194, 2017 | 66 | 2017 |
Current ethical and legal issues in health-related direct-to-consumer genetic testing E Niemiec, L Kalokairinou, HC Howard Personalized Medicine 14 (5), 433-445, 2017 | 43 | 2017 |
Current developments in the regulation of direct-to-consumer genetic testing in Europe L Kalokairinou, HC Howard, P Borry Medical Law International 15 (2-3), 97-123, 2015 | 15 | 2015 |
Regulating the advertising of genetic tests in Europe: a balancing act L Kalokairinou, P Borry, HC Howard Journal of Medical Genetics 54 (10), 651-656, 2017 | 14 | 2017 |
Direct‐to‐Consumer Genetic Testing L Kalokairinou, HC Howard, P Borry eLS, 2014 | 14 | 2014 |
Changes on the horizon for consumer genomics in the EU L Kalokairinou, HC Howard, P Borry Science 346 (6207), 296-298, 2014 | 12 | 2014 |
Ethical and legal considerations of alternative neurotherapies A Nagappan, L Kalokairinou, A Wexler AJOB neuroscience 12 (4), 257-269, 2021 | 10 | 2021 |
The promise of direct-to-consumer COVID-19 testing: ethical and regulatory issues L Kalokairinou, PJ Zettler, A Nagappan, MA Kyweluk, A Wexler Journal of Law and the Biosciences 7 (1), lsaa069, 2020 | 10 | 2020 |
Attitudes of cystic fibrosis patients and their parents towards direct-to-consumer genetic testing for carrier status S Janssens, L Kalokairinou, D Chokoshvilli, C Binst, I Mahieu, ... Personalized Medicine 12 (2), 99-107, 2015 | 8 | 2015 |
‘It’s much more grey than black and white’: clinical geneticists’ views on the oversight of consumer genomics in Europe L Kalokairinou, P Borry, HC Howard Personalized Medicine 17 (2), 129-140, 2020 | 7 | 2020 |
Neurofeedback as placebo: a case of unintentional deception? L Kalokairinou, LS Sullivan, A Wexler Journal of medical ethics 48 (12), 1037-1042, 2022 | 6 | 2022 |
Attitudes and experiences of European clinical geneticists towards direct-to-consumer genetic testing: a qualitative interview study L Kalokairinou, P Borry, HC Howard New Genetics and Society 38 (4), 410-429, 2019 | 3 | 2019 |
Current ethical issues related to the implementation of whole-exome and whole-genome sequencing P Borry, D Chokoshvili, E Niemiec, L Kalokairinou, DF Vears, HC Howard Movement Disorder Genetics, 481-497, 2015 | 3 | 2015 |
Policies of US Companies Offering Direct-to-Consumer Laboratory Tests L Kalokairinou, R Choi, NY Wei, A Wexler JAMA Internal Medicine 183 (11), 1275-1278, 2023 | 2 | 2023 |
Opportunity Cost or Opportunity Lost: An Empirical Assessment of Ethical Concerns and Attitudes of EEG Neurofeedback Users L Kalokairinou, R Choi, A Nagappan, A Wexler Neuroethics 15 (3), 28, 2022 | 1 | 2022 |
Ethical issues in direct-to-consumer healthcare: A scoping review A Nagappan, L Kalokairinou, A Wexler PLOS Digital Health 3 (2), e0000452, 2024 | | 2024 |
Promotion and sales of self-tests on the Internet E Sleurs, L Kalokairinou, HC Howard, P Borry Routledge Handbook of Medical Law and Ethics, 286-300, 2014 | | 2014 |